AR-501, an inhaled formulation of gallium citrate, is a small molecule anti-infective with broad spectrum activity against Gram-negative and Gram-positive bacteria in vitro, including ...
- AR-501 Phase 2a received recommendations to proceed from the Data Safety Monitoring Board (DSMB) from the CF Foundation and study's Safety Monitoring Committee (SMC) SAN JOSE, Calif., June 22, 2020 ...
SAN JOSE, Calif., June 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies for ...
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 (GLOBE ...
The Food and Drug Administration (FDA) yesterday said that a Gallium citrate GA 67 injection used to diagnose Hodgkin’s disease, lymphoma and bronchogenic carcinoma would soon face a supply shortage, ...
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA ...
Aridis Pharmaceuticals (NASDAQ:ARDS) inhaled drug AR-501 met its main and secondary goals of safety and pharmacokinetics in a phase 2a trial to treat patients with cystic fibrosis (CF) who have ...
Impact of PSMA PET/CT on SRT planning: Preliminary results from the randomized phase III trial NCT03582774. Radiographic findings on conventional (CT, 99mTc-HDP) and 68 Ga-citrate PET imaging in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback